prostate cancer
Conditions
Interventions
Measure the displacement of needle applicator according to the gold marker inserted in prostate by CT during high dose rate interstitial monothreapy treatment period
Sponsors
Osaka University Graduate School of Medicine, Dept of Radiation Oncology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: *Histologically proven prostate cancer *Any Gleason Score *Any pretreatment PSA *Any T stage *Clinicaly diagnosed as N0M0 with MRI, bone scan, CT and so on. *Use UICC TNM2009 for staging. *ECOG performance status 0 or 1. *Blood test results are compatible with criterias as below. WBC>=3000/ul, Hb>=10.0g/dl, Plt>=100000/ul, Cre>=2.0 mg/dl, GOT>=100U/L, GPT<=100U/L *Without any history of local therapy such as operation, trans-urethral procedure, hyperthermia. Hormonal therapy is permitted. *Informed concented cases.
Exclusion criteria
Exclusion criteria: *Case having an active synchronous double cancer. *Case having an uncontrollable diabetes . *Case having a complication that doesn't quit internal use of anticoagulant. *Case having a serious cranial nerve disease *Case having collagenosis *The case that the examination medical attendant judged to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The displacement measurement of the applicator for the marker in the prostate during the prostatic monotherapy period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the change of DVH of OAR and CTV with the displacement. | — |
Countries
Japan
Contacts
Public ContactOsamu Suzuki
Osaka University Graduate School of Medicine Radiation Oncology
Outcome results
None listed